[HTML][HTML] Secukinumab: a review in psoriatic arthritis
HA Blair - Drugs, 2021 - Springer
Secukinumab (Cosentyx®) is a fully human monoclonal antibody that selectively targets
interleukin (IL)-17A, a proinflammatory cytokine involved in the pathogenesis of psoriatic …
interleukin (IL)-17A, a proinflammatory cytokine involved in the pathogenesis of psoriatic …
[HTML][HTML] Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials
X Huang, H Shentu, Y He, H Lai, C Xu, M Chen… - Immunologic …, 2023 - Springer
In recent years, the use of interleukin (IL) 23 inhibitors in the treatment of psoriatic arthritis
(PsA) has been the subject of much research. By specifically binding to the p19 subunit of IL …
(PsA) has been the subject of much research. By specifically binding to the p19 subunit of IL …
The updated GRAPPA and EULAR recommendations for the management of psoriatic arthritis: similarities and differences
L Coates, L Gossec - Joint Bone Spine, 2023 - Elsevier
Management recommendations are helpful for clinicians and patients because they provide
guidelines for the use of medications [1]. In psoriatic arthritis (PsA), several recommendation …
guidelines for the use of medications [1]. In psoriatic arthritis (PsA), several recommendation …
IL-23/IL-17 axis in inflammatory rheumatic diseases
In inflammatory rheumatic disorders, the immune system attacks and damages the
connective tissues and invariably internal organs. During the past decade, remarkable …
connective tissues and invariably internal organs. During the past decade, remarkable …
Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics …
B Glintborg, D Di Giuseppe, JK Wallman… - Annals of the …, 2023 - ard.bmj.com
Background We aimed to describe the uptake of newer biologic or targeted synthetic
disease-modifying antirheumatic drugs (b/tsDMARDs) in psoriatic arthritis (PsA) in the …
disease-modifying antirheumatic drugs (b/tsDMARDs) in psoriatic arthritis (PsA) in the …
[HTML][HTML] New insights in physical therapy and rehabilitation in psoriatic arthritis: a review
FM Perrotta, S Scriffignano, D Benfaremo… - Rheumatology and …, 2021 - Springer
Psoriatic arthritis (PsA) is a complex, multiform and chronic inflammatory disease
characterized by the association of psoriasis and arthritis with other musculoskeletal and …
characterized by the association of psoriasis and arthritis with other musculoskeletal and …
Real‐World Evidence Assessing Psoriatic Arthritis by Disease Domain: An Evaluation of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
PJ Mease, J O'Brien, N Middaugh… - ACR Open …, 2023 - Wiley Online Library
Objective Real‐world studies assessing treatment response by psoriatic arthritis (PsA)
domains are limited. This study aimed to describe the patient characteristics, frequency and …
domains are limited. This study aimed to describe the patient characteristics, frequency and …
[HTML][HTML] A neutrophil-driven inflammatory signature characterizes the blood transcriptome fingerprint of psoriasis
Transcriptome profiling approaches have been widely used to investigate the mechanisms
underlying psoriasis pathogenesis. Most researchers have measured changes in transcript …
underlying psoriasis pathogenesis. Most researchers have measured changes in transcript …
Toxicity signals associated with secukinumab: A pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System …
Y Zheng, X Guo, C Chen, L Chi, Z Guo… - British Journal of …, 2023 - Wiley Online Library
Aims Secukinumab, the first interleukin 17A inhibitor, is widely used to treat immune
diseases, including plaque psoriasis, psoriatic arthritis and ankylosing spondylitis. Recently …
diseases, including plaque psoriasis, psoriatic arthritis and ankylosing spondylitis. Recently …
[HTML][HTML] A framework for longitudinal latent factor modelling of treatment response in clinical trials with applications to Psoriatic Arthritis and Rheumatoid Arthritis
Objective: Clinical trials involve the collection of a wealth of data, comprising multiple
diverse measurements performed at baseline and follow-up visits over the course of a trial …
diverse measurements performed at baseline and follow-up visits over the course of a trial …